Invasive Lobular Carcinoma: Stephanie's Patient Story
This breast cancer diagnosis at a glance
- Subtype
- Invasive Lobular Carcinoma
- Sex
- Female
- Treatment
- surgery, chemotherapy, hormone therapy and targeted therapy
- Outcome
- Care Ongoing
Treatment course, step by step
- 2004 mammogram finding
- needle-localized biopsy, lumpectomy, and sentinel node biopsy
- DCIS on right side and extensive LCIS
- single mastectomy and reconstruction
- chemotherapy
- 5 years of Tamoxifen
- July 2018 right axillary pain/lump
- biopsy first called ductal breast cancer; CT showed no metastasis
- MRI showed right axillary lymph node mass and likely chest-wall cancer
- October 2018 12-hour surgery removing multiple lymph nodes, 4 ribs, and lower sternum; margins not clean because spread was extensive
- diagnosis clarified as ILC
- Ibrance plus Femara, additional surgeries, and later recurrence in initial area
- February scans showed no new cancer growth
- continue Femara without chemotherapy.
What happened, in summary
Stephanie was 68 when she shared a long breast cancer history. In 2004, a routine mammogram found an abnormality on the right side. She had a needle-localized biopsy, lumpectomy, and sentinel node biopsy, then was diagnosed with ductal carcinoma in situ and extensive lobular carcinoma in situ. Treatment included single mastectomy, reconstruction, chemotherapy, and 5 years of Tamoxifen. For years, she had mammograms and follow-up visits, but no additional imaging on the right side. In July 2018, after lifting and moving items, she felt pain and a lump in her right axilla. Biopsy first labeled it ductal breast cancer. CT scans showed no metastasis, but MRI found a right axillary lymph node mass and a concerning chest-wall area. In October 2018, Stephanie had a 12-hour surgery that removed multiple lymph nodes, 4 ribs, and part of the lower sternum. Margins were not clean because the spread was extensive, and doctors later clarified that the cancer was invasive lobular carcinoma. Since then, she has had Ibrance, Femara, additional surgeries, and recurrence in the original area. As of February 2022, recent scans showed no new cancer growth, and she continued Femara without chemotherapy. Her experience shows why long-term follow-up and subtype awareness matter after lobular disease.
Where this story comes from
This is a lay summary of an account first published by Lobular Breast Cancer Alliance. Read the original in full
How we source and attribute stories Accuracy and limitations
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team. Read the full disclaimer